Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.83 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | NOS2 | P35228 | 6/20 | 0.50 |
| ▸ | NOS1 | P29475 | 4/20 | 0.50 |
| ▸ | NOS3 | P29474 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL15753994 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL19742881 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL1433568 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL5581427 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL302610 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL301792 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL28318609 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL1696587 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL7861429 | 1.00 | GSR (0.83) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL9448118 | 0.98 | GSR (0.80) | GSRARG2ARG1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024980-A1 | LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF | BIOPHARMA CREDIT PLC (GB) | 2022-01-27 | — | — | US | disclosed |
| US-20210388028-A1 | GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF | BIOPHARMA CREDIT PLC (GB) | 2021-12-16 | — | — | US | disclosed |
| US-11137392-B2 | Cantilever sensors for molecule detection | 3P SENSE LIMITED (GB) | 2021-10-05 | — | — | US | disclosed |
| EP-3883589-A1 | LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF | Insmed Incorporated (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3883590-A1 | GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF | Insmed Incorporated (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20200033329-A1 | CANTILEVER SENSORS FOR MOLECULE DETECTION | 3P SENSE LIMITED (GB) | 2020-01-30 | — | — | US | disclosed |
| US-10471149-B2 | Stabilized vancomycin formulations | INSMED INCORPORATED (US) | 2019-11-12 | — | — | US | disclosed |
| US-10458980-B2 | Cantilever sensors for molecule detection | 3P SENSE LIMITED (GB) | 2019-10-29 | — | — | US | disclosed |
| EP-2925298-B1 | STABILIZED VANCOMYCIN FORMULATIONS | INSMED INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20190022232-A1 | STABILIZED VANCOMYCIN FORMULATIONS | INSMED INCORPORATED | 2019-01-24 | — | — | US | disclosed |
| US-20040191125-A1 | Devices and methods for using centripetal acceleration to drive fluid movement on a microfluidics platform | KELLOGG GREGORY (US) | 2004-09-30 | — | — | US | disclosed |
| US-6719682-B2 | Electronic spindle for using centripetal acceleration to drive fluid movement in a microfluidics system | TECAN TRADING AG (CH) | 2004-04-13 | — | — | US | disclosed |
| US-20030195106-A1 | Devices and methods for using centripetal acceleration to drive fluid movement on a microfluidics platform | TECAN TRADING AG (CH) | 2003-10-16 | — | — | US | disclosed |
| US-6399361-B2 | RESISTIVE HEATER ELEMENT COMPRISING ELECTRICALLY INERT SUBSTRATE CAPABLE OF BEING SCREEN PRINTED WITH CONDUCTIVE INK AND RESISTIVE INK, CONDUCTIVE INK AND RESISTIVE INK SCREEN-PRINTED IN PATTERNS IN CONTACT, PRODUCING HEAT | TECAN TRADING AG (CH) | 2002-06-04 | — | — | US | disclosed |
| US-20020027133-A1 | Device and methods for using centripetal acceleration to drive fluid movement in a microfluidics system | GAMERA BIOSCIENCE CORPORATION | 2002-03-07 | — | — | US | disclosed |
| US-20010001060-A1 | Devices and methods for using centripetal acceleration to drive fluid movement in a microfluidics system | TECAN BOSTON, INC. | 2001-05-10 | — | — | US | disclosed |
| US-6063589-A | Devices and methods for using centripetal acceleration to drive fluid movement on a microfluidics system | GAMERA BIOSCIENCE CORPORATION (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0983504-A2 | DEVICES AND METHODS FOR USING CENTRIPETAL ACCELERATION TO DRIVE FLUID MOVEMENT IN A MICROFLUIDICS SYSTEM | GAMERA BIOSCIENCE CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998053311-A9 | DEVICES AND METHODS FOR USING CENTRIPETAL ACCELERATION TO DRIVE FLUID MOVEMENT IN A MICROFLUIDICS SYSTEM | GAMERA BIOSCIENCE CORP (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1998053311-A2 | DEVICES AND METHODS FOR USING CENTRIPETAL ACCELERATION TO DRIVE FLUID MOVEMENT IN A MICROFLUIDICS SYSTEM | GAMERA BIOSCIENCE CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471149-B2 | Stabilized vancomycin formulations | CETP, PCSK9, HDLBP | GSR 3013/4885ARG2 3588/4885ARG1 1911/4885 |
| US-20220024980-A1 | LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF | PGLS, LGALS3BP, LNPEP | GSR 1981/4885ARG2 2614/4885ARG1 1451/4885 |
| US-20190022232-A1 | STABILIZED VANCOMYCIN FORMULATIONS | CETP, PCSK9, HDLBP | GSR 3013/4885ARG2 3588/4885ARG1 1911/4885 |
| US-20210388028-A1 | GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF | ALG1, ALG8, MUC1 | GSR 3965/4885ARG2 1150/4885ARG1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.